Patents Issued in February 18, 2014
-
Patent number: 8653106Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: July 30, 2010Date of Patent: February 18, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Patent number: 8653107Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed.Type: GrantFiled: July 22, 2011Date of Patent: February 18, 2014Assignee: Takeda Pharma A/SInventors: Jesper Grarup, Hanne Wulf Nielsen
-
Patent number: 8653108Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.Type: GrantFiled: May 17, 2012Date of Patent: February 18, 2014Assignee: Southwest Research InstituteInventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
-
Patent number: 8653109Abstract: The present invention relates to novel substituted 2,4?- and 3,4?-bipyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.Type: GrantFiled: August 30, 2007Date of Patent: February 18, 2014Assignee: Bayer Intellectual Property GmbHInventors: Peter Nell, Walter Hübsch, Barbara Albrecht-Küpper, Joerg Keldenich, Andreas Knorr
-
Patent number: 8653110Abstract: Disclosed are novel active compound combinations comprising at least one substituted enaminocarbonyl compound and azadirachtin, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids. Methods of controlling insects and acarids are also disclosed.Type: GrantFiled: February 4, 2011Date of Patent: February 18, 2014Assignee: Bayer CropScience AGInventors: Michael Kilian, Margit Doth
-
Patent number: 8653111Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: GrantFiled: January 23, 2012Date of Patent: February 18, 2014Assignee: Bayer Intellectual Property GmbHInventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
-
Patent number: 8653112Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: GrantFiled: October 6, 2010Date of Patent: February 18, 2014Assignee: Karo Bio ABInventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
-
Patent number: 8653113Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.Type: GrantFiled: May 26, 2011Date of Patent: February 18, 2014Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Hisaya Nishide, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
-
Patent number: 8653114Abstract: The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.Type: GrantFiled: June 1, 2011Date of Patent: February 18, 2014Assignee: Bayer Intellectual Property GmbHInventors: Jörg Nico Greul, Jürgen Benting, Peter Dahmen, Ulrike Wachendorff-Neumann
-
Patent number: 8653115Abstract: The invention relates a kind of antiviral agents, more concretely, relates to a kind of heterocyclic non-nucleoside compounds with the following structures, their preparation and pharmaceutical compositions including the compounds. The said compounds can be used as antiviral agents and as medicaments for treating diseases such as hepatitis B, influenza, herpes, HIV and so on.Type: GrantFiled: June 13, 2007Date of Patent: February 18, 2014Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Fajun Nan, Jianping Zuo, Haijun Chen, Guifeng Wang, Min Gu, Fenghua Zhu, Wei Tang
-
Patent number: 8653116Abstract: The invention relates to new isoxazoline compounds of formula wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful in the control of parasites, in particular ectoparasites, in and on warm-blooded animals.Type: GrantFiled: January 14, 2013Date of Patent: February 18, 2014Assignee: Novartis AGInventors: Steve Nanchen, Noelle Gauvry, Thomas Goebel
-
Patent number: 8653117Abstract: The invention concerns a composition containing at least an oxazolin, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an alkanolamide, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such composition on the skin and/or mucosa.Type: GrantFiled: January 13, 2009Date of Patent: February 18, 2014Assignee: Laboratoires ExpanscienceInventors: Philippe Msika, Nathalie Piccardi, Antoine Piccirilli
-
Patent number: 8653118Abstract: The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfon-amido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R1 is selected from the group consisting of CO2R7 and CON(R7)SO2R7 wherein R1, R2, R3, R4, and R7 are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, EP3, TP and/or EP4 receptor mediated diseases or conditions.Type: GrantFiled: August 19, 2011Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Jose L. Martos, William R. Carling, David F. Woodward, Jenny W. Wang, Jussi J Kangasmetsa
-
Patent number: 8653119Abstract: Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.Type: GrantFiled: November 22, 2011Date of Patent: February 18, 2014Assignee: The Scripps Research InstituteInventors: Jeffery W. Kelly, Evan T. Powers, Hossein Razavi
-
Patent number: 8653120Abstract: Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors.Type: GrantFiled: December 2, 2008Date of Patent: February 18, 2014Assignee: Apkarian Technologies LLCInventor: A. Vania Apkarian
-
Patent number: 8653121Abstract: An agrochemical composition comprises an azole active ingredient and an N,N-dialkyl long chain alkylamide. The N,N-dialkyl long chain alkylamide is present in sufficient amount to prevent or inhibit the crystallization of the azole derivative during the application of the composition to a locus. Preferred N,N-Dialkyl long chain alkylamide(s) comprised in the composition is/are selected from the group consisting of compounds of the formula (I): in which (a) R1 and R2 are independently normal alkyl radicals having 2 carbon atoms, and R represents an alkyl group having from 10 to 30 carbon atoms; or (b) R1 and R2 are independently normal alkyl radicals having 3 carbon atoms, and R represents an alkyl group having from 9 to 30 carbon atoms; or 20 (c) R1 and R2 are independently normal alkyl radicals having from 4 to 20 carbon atoms and R represents an alkyl group having from 6 to 30 carbon atoms.Type: GrantFiled: May 28, 2008Date of Patent: February 18, 2014Assignee: Rotam Agrochem International Co., Ltd.Inventors: Amanda Yin, Sonia Chen, Yifan Wu, Pichumani Narayanamoorthy, Chang Yuan Lo
-
Patent number: 8653122Abstract: An oromucosal formulation containing as an active ingredient a substituted imidazole derivative of formula (I) where Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt of this imidazole derivative, and a process for its preparation.Type: GrantFiled: November 10, 2003Date of Patent: February 18, 2014Assignee: Santhera Pharmaceuticals (Switzerland) Ltd.Inventors: Juha-Matti Savola, Päivi Juujärvi, Jukka Ilkka
-
Patent number: 8653123Abstract: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl) -2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: GrantFiled: September 15, 2011Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Mohammad I. Dibas, Daniel W. Gil, Ken Chow, Liming Wang, Michael E. Garst, John E. Donello
-
Patent number: 8653124Abstract: Disclosure is provided for imidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.Type: GrantFiled: February 2, 2011Date of Patent: February 18, 2014Assignee: North Carolina State UniversityInventors: Christian Melander, John Cavanagh, Robert W. Huigens, III, T. Eric Ballard, Justin J. Richards
-
Patent number: 8653125Abstract: The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted aryl or heterocyclyl; a combination of X and Y is a combination selected from (X, Y)?(C(?O)N(R1), C(?O)N(R2)), (C(?O)N(R1), imidazole-1,3-diyl), (N(R1), C(?O)N(R2)), (O, C(?O)N(R2)), (C(R3)(R4), N(R2)) or (a single bond, C(?O)N(R2)); R1, R2 and R3 are independently hydrogen or substituted or unsubstituted alkyl; R5 is substituted or unsubstituted aryl or heterocyclyl; R6 is halogen, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy; m is 0 or 1; and n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or fused bicyclic heterocycle.Type: GrantFiled: March 5, 2010Date of Patent: February 18, 2014Assignee: Shionogi Co., Ltd.Inventors: Hiroshi Yoshida, Keisuke Tonogaki, Masahiro Sakagami, Kenji Takaya
-
Patent number: 8653126Abstract: To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): or the general formula (II): or an isotope thereof or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 17, 2011Date of Patent: February 18, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Nobuo Machinaga, Jun Chiba, Fumihito Muro, Hiroshi Yuita, Jun Watanabe
-
Patent number: 8653127Abstract: The present invention provides substituted pyrazolo-heterocycles having the general structure of formula I The structures of rings A and B and substituents Ra, Rb and Rc are described in the specification. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis, treatment and inhibition of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.Type: GrantFiled: January 14, 2010Date of Patent: February 18, 2014Assignee: Cara Therapeutics, Inc.Inventor: Robert Zhiyong Luo
-
Patent number: 8653128Abstract: A stable liquid pharmaceutical formulation containing an N-phenylpyrazole derivative, a crystallization inhibitor/viscolizer and a solvent/co-solvent system comprised of a glycol ether solvent and at least one mono alkyl ester co-solvent; and the use of such a formulation for the prevention and/or treatment of infestations with fleas and ticks.Type: GrantFiled: March 23, 2012Date of Patent: February 18, 2014Inventor: Jugal K. Taneja
-
Patent number: 8653129Abstract: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.Type: GrantFiled: April 11, 2011Date of Patent: February 18, 2014Assignee: M. Alphabet 1, LLCInventors: Howard Fein, Mindy B. Berlin
-
Patent number: 8653130Abstract: A method by which the physiological activities of sesamin-class compounds can be efficiently exhibited and enhanced, as well as an effective compound that can be combined with the sesamin-class compounds to this end. By using sesamin-class compounds in combination with more than specified proportions of arachidonic acid class compounds, the physiological activities of the sesamin-class compounds, for example, their anti-fatigue action is synergistically enhanced to provide compositions that are safe in humans and non-human animals and which hence can be ingested continuously.Type: GrantFiled: September 17, 2008Date of Patent: February 18, 2014Assignee: Suntory Holdings LimitedInventors: Daisuke Takemoto, Masanori Kontani, Yoshiko Ono, Yoko Yasutake
-
Patent number: 8653131Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: GrantFiled: August 21, 2009Date of Patent: February 18, 2014Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventors: Guohan Yang, Ton That Hai, Bennett P. Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Patent number: 8653132Abstract: The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.Type: GrantFiled: March 15, 2013Date of Patent: February 18, 2014Assignee: Ohio UniversityInventor: Rathindra N. Bose
-
Patent number: 8653133Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: GrantFiled: April 18, 2011Date of Patent: February 18, 2014Assignee: LEO Laboratories LimitedInventor: Steven Martin Ogbourne
-
Patent number: 8653134Abstract: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.Type: GrantFiled: December 22, 2005Date of Patent: February 18, 2014Assignee: Merck Patent GmbHInventors: Catherine Vidal, Nathalie Adje, Stéphane Yvon, Jean Jacques Zeiller
-
Patent number: 8653135Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.Type: GrantFiled: February 7, 2007Date of Patent: February 18, 2014Assignee: Sovereign Pharmaceuticals, LLCInventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
-
Patent number: 8653136Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryphtophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.Type: GrantFiled: April 17, 2008Date of Patent: February 18, 2014Assignee: Determinants of Metabolism Research Laboratory S.R.L.Inventors: Franco Conti, Francesco Saverio Dioguardi
-
Patent number: 8653137Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.Type: GrantFiled: June 7, 2013Date of Patent: February 18, 2014Assignee: United Therapeutics CorporationInventors: Roger Andrew Jeffs, David Zaccardelli
-
Patent number: 8653138Abstract: The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1, and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.Type: GrantFiled: July 1, 2011Date of Patent: February 18, 2014Assignee: 4SC MGInventors: Aldo Ammendola, Julia Diederichs, Johann Leban, Daniel Vitt
-
Patent number: 8653139Abstract: The invention relates to drug substance preparations, pharmaceutical compositions and dosage forms containing (R)-(?)-2-(2-fluoro-4-biphenylyl) propionic acid as the active pharmaceutical ingredient, and limited amounts of specific product-related and process-related impurities.Type: GrantFiled: July 31, 2009Date of Patent: February 18, 2014Assignee: Aesica Pharmaceuticals LimitedInventors: Gaylen M. Zentner, James C. McRea, Mark S. Williams, Stephen J. Martin, Norman T. Smith, Catriona A. Oare
-
Patent number: 8653140Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.Type: GrantFiled: May 18, 2012Date of Patent: February 18, 2014Assignee: Galderma Research & DevelopmentInventors: Michael Graeber, Janusz Czernielewski
-
Patent number: 8653141Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: GrantFiled: April 19, 2012Date of Patent: February 18, 2014Assignee: AbbVie Inc.Inventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
-
Patent number: 8653142Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: GrantFiled: March 7, 2013Date of Patent: February 18, 2014Assignee: Acucela Inc.Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Ryo Kubota
-
Patent number: 8653143Abstract: The present invention relates to a novel use of a panduratin derivative or a Boesenbergia pandurata extract. More specifically, the invention relates to a composition for preventing and treating/relieving a metabolic disease selected from a group consisting of obesity, hyperlipidemia, hypercholesterolemia and diabetes, containing a panduratin derivative represented by Chemical Formula 1, 2 or 3 or a Boesenbergia pandurata extract as an active ingredient, a method for treating a metabolic disease selected from a group consisting of obesity, hyperlipidemia, hypercholesterolemia and diabetes, by administering an effective amount of the panduratin derivative or the Boesenbergia pandurata extract to a subject in need thereof, and a use of the panduratin derivative or the Boesenbergia pandurata extract to prepare a reagent for preventing and treating/relieving a metabolic disease selected from a group consisting of obesity, hyperlipidemia, hypercholesterolemia and diabetes.Type: GrantFiled: October 9, 2009Date of Patent: February 18, 2014Assignees: Newtree Co., Ltd.Inventors: Jae-Kwan Hwang, Do Un Kim
-
Patent number: 8653144Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.Type: GrantFiled: October 12, 2012Date of Patent: February 18, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Viktoria Kheifets
-
Patent number: 8653145Abstract: The present invention is a method for alleviating at least one climacteric symptom in a climacteric subject using an anticholinergic agent. To illustrate the instant invention, homatropine was shown to relieve hot flushes in peri-menopausal and post-menopausal women.Type: GrantFiled: September 19, 2006Date of Patent: February 18, 2014Assignee: Eaton Scientific Systems, Ltd.Inventors: Hootan Melamed, Edward Withrow, III, Jennifer Berman
-
Patent number: 8653146Abstract: The present application relates to a method for treating or preventing Th17 inflammatory disease mediated with IL-6 or IL-17 by administration of medication which inhibits vascular endothelial growth factor receptors, and a pharmaceutical composition therefor.Type: GrantFiled: May 20, 2010Date of Patent: February 18, 2014Assignee: Postech Academy-Industry FoundationInventors: Yoon Keun Kim, Yong Song Gho, Yu Sun Kim
-
Patent number: 8653147Abstract: The present invention discloses an inorganic/organic mixed component (I/O) dispersant and applications thereof, which is primarily applied to dispersing nanoparticles of metal oxides. The I/O dispersant of the present invention can be a composite of inorganic clay and an organic surfactant, a composite of inorganic clay and polyoxyalkylene-amine, or a composite of inorganic clay, polyisobutylene succinic anhydride (PIB-SA) and hydrochloric acid salt or tetraalkyl quaternary salt of polyoxyalkylene-amine, or fatty amines. By mixing with the I/O dispersant of the present invention, nanoparticles of a metal oxide can be uniformly dispersed without aggregation particularly at high solid content. The dispersion has a lower viscosity and is relatively stable in storage even at high temperature.Type: GrantFiled: November 20, 2011Date of Patent: February 18, 2014Assignee: National Taiwan UniversityInventors: Jiang-Jen Lin, Yen-Chi Hsu, Ming-Li Chiang, Chien-Chia Chu
-
Patent number: 8653148Abstract: A oil and water emulsion breaking system having a reactor including an inner vessel connected to an inlet and an outlet of the reactor and allowing microwaves to pass therethrough, a packed bed of activated carbon retained within and across the inner vessel along at least part of a length thereof and configured for circulation of the emulsion therethrough, and a microwave applicator configured to direct microwaves to the packed bed through the inner vessel.Type: GrantFiled: October 22, 2010Date of Patent: February 18, 2014Assignee: C-Micro Systems Inc.Inventor: Chang Yul Cha
-
Patent number: 8653149Abstract: The present invention relates to processes and apparatuses for generating light olefins, methane and other higher-value gaseous hydrocarbons from “liquid” heavy hydrocarbon feedstocks.Type: GrantFiled: May 26, 2011Date of Patent: February 18, 2014Assignee: GreatPoint Energy, Inc.Inventors: Earl T. Robinson, Pattabhi K. Raman, Wenyuan Wu
-
Patent number: 8653150Abstract: The present invention relates to a method for decomposing, in the presence of subcritical water, a thermosetting resin comprising a polyester moiety and a crosslinking moiety therewith to provide a compound comprising an acid residue derived from the polyester moiety and a residue derived from the crosslinking moiety, and collecting the compound in an efficient yield, specifically, which comprises steps of: (I) decomposing the thermosetting resin in the presence of subcritical water to provide a solid comprising a compound comprising an acid residue derived from the polyester moiety and a residue derived from the crosslinking moiety, (II) subjecting the solid to an organic solvent to dissolve the compound into the organic solvent, wherein the organic solvent has a higher solubility which can dissolve the compound than that of water, and (III) collecting, separating or isolating the compound from the organic solvent.Type: GrantFiled: March 26, 2009Date of Patent: February 18, 2014Assignees: Panasonic Corporation, International Center for Environmental Technology TransferInventors: Takumi Izumitani, Takaharu Nakagawa, Masaru Hidaka, Keishi Shibata, Junko Matsui
-
Patent number: 8653151Abstract: The present invention is directed to articles of manufacture having at least a portion prepared using recycled material, including but not limited recycled rubber or other polymeric materials. The articles may incorporate the recycled materials in a granulated form. In specific embodiments, the article comprises an article of footwear (i.e., a shoe). Particularly, all or part of the shoe sole may be formed using the granulated material, the granules specifically being joined together using a binder material, such as a polyurethane, preferably a moisture cure, single component polyurethane binder. The invention further provides methods of preparing articles formed of granulated materials. The inventive methods are characterized by their excellent economic benefits, ease of use, and environmental benefits.Type: GrantFiled: September 23, 2008Date of Patent: February 18, 2014Assignee: Aetrex Worldwide, Inc.Inventors: Joseph J. Skaja, Evan L. Schwartz
-
Patent number: 8653152Abstract: The present invention relates to a porous resin bead containing a first aromatic monovinyl compound-divinyl compound-(meth)acrylonitrile-second aromatic monovinyl compound copolymer, in which the second aromatic monovinyl compound contains a group capable of binding with a carboxyl group by dehydration condensation reaction, and in which the porous resin bead has a dry volume of from 2 to 3 ml/g.Type: GrantFiled: September 16, 2010Date of Patent: February 18, 2014Assignee: Nitto Denko CorporationInventors: Kenjiro Mori, Tatsuya Konishi, Eri Maeta
-
Patent number: 8653153Abstract: A violet radiation curable ink including at least one curable monomer, at least one organic gellant, at least one photoinitiator, and at least one colorant, wherein the ink exhibits a reflectance on a substrate at a loading of from about 2 mg/inch2 to about 7 mg/inch2 that ranges from 50% to about 60% at a wavelength of 500 nm and that ranges from 0% to about 10% at a wavelength of about 600 nm. Also, the violet ink substantially matches PANTONE® Violet.Type: GrantFiled: December 18, 2012Date of Patent: February 18, 2014Assignee: Xerox CorporationInventors: Daryl W Vanbesien, Barkev Keoshkerian, Naveen Chopra, Michelle N Chretien, Jenny Eliyahu, Nathan M Bamsey
-
Patent number: 8653154Abstract: Oxidation resistant crosslinked ultrahigh molecular weight polyethylene (UHMWPE) is described, wherein at least two different additives in the manufacture synergistically increase the oxidation resistance of crosslinked UHMWPE. This allows the manufacture of oxidation resistant crosslinked UHMWPE using lower levels of additives and/or lower levels of crosslinking irradiation or chemicals. The lower levels of additives and/or crosslinking produce crosslinked UHMWPE having desired physical properties not possible without the synergistic interaction of the additives. This crosslinked UHMWPE may be used in medical prostheses such as in bearing components having desired physical properties such as wear resistance and oxidation resistance not possible without the synergistic interaction of the additives.Type: GrantFiled: May 4, 2010Date of Patent: February 18, 2014Assignee: Smith & Nephew, Inc.Inventors: Mark L. Morrison, Vivek D. Pawar, Lorenz Brunner, Shilesh C. Jani
-
Patent number: 8653155Abstract: The present invention pertains, among other things, to polymers having one or more lipophilic hydrocarbon segments and one or more biodegradable polymeric segments, to methods of making such polymers and to products formed using such polymers.Type: GrantFiled: August 12, 2010Date of Patent: February 18, 2014Assignee: Boston Scientific Scimed, Inc.Inventors: J. Thomas Ippoliti, Joshua Speros, Scott Schewe, Robert W. Warner, Dan Everson